July 24, 2025

Michael Platten Appointed “Ambassador” of European Research Council

Michael Platten Appointed “Ambassador” of European Research Council

The scientist from Heidelberg University is to boost trust in the funding of innovative research

Prof. Dr Michael Platten has been appointed “Ambassador for the ERC” in order to engage with the public and decision-makers about the importance of groundbreaking research and its benefit for society and industry. The neurologist is one of two scientists in Germany selected for this ambassador network by the European Research Council (ERC) and the Association of ERC Grantees (AERG). A total of 32 outstanding researchers funded with an ERC Grant have been appointed ambassadors. Michael Platten, holder of a professorship at the Medical Faculty Mannheim of Heidelberg University, works at Mannheim University Hospital and the German Cancer Research Center (DKFZ).

Porträt Michael Platten
Michael Platten | © Medizinische Fakultät Mannheim der Universität Heidelberg

In his function as ERC ambassador in Germany, Prof. Platten is mandated to contribute to communicating the value of basic research to political decision-makers, the media, and the public. This includes highlighting the contribution it makes in dealing with societal, economic, environmental and political challenges. Another key concern is to boost trust in funding for innovative research. At the same time, the scientist is a contact partner for European Research Council grantees and he is expected to inform talented researchers about the financial opportunities offered by the ERC. The office of ambassador is initially for one year and can be extended up to six times.

Michael Platten is the director of the Department of Neurology at Mannheim University Hospital and director of the Mannheim Center for Translational Neuroscience, located at the Medical Faculty Mannheim of Heidelberg University. In addition, he heads the Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology at the German Cancer Research Center. In 2024 he received an ERC Advanced Grant, which funds groundbreaking research projects. In the framework of his ERC project at the DKFZ, Prof. Platten and his team are working on developing and optimizing personalized cell-based, AI-controlled immunotherapies for malignant brain tumors.

The European Research Council is an institution established by the European Commission to finance frontier research – groundbreaking, visionary research that crosses classical borders. The Association of ERC Grantees is an international organization with a current membership of approx. 10,000 ERC grantees past and present. The ERC and AERG hope to expand the “Ambassadors for the ERC” network in the future to more European Union member states and associated countries.

Our latest News

discover more
European Biotech Act: bioRN brings Industry and Policymakers together

European Biotech Act: bioRN brings Industry and Policymakers together

How can Europe strengthen its global competitiveness in biotechnology? Heidelberg, July 7th: This question was at the heart of a high-level roundtable hosted by the bioRN Life Science Cluster with Member of the European Parliament Hildegard Bentele. Representatives from Ascendis Pharma, BD, PROGEN, Novaliq, BASF Agricultural Solutions, PEPperPRINT, Evotec and Isenbruck Bösl Hörschler joined the […]

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

NORTH CHICAGO, Ill., July 6, 2026 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization for TEPKINLY® (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R2) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The approval is based on results from the pivotal Phase 3 […]

Optimized Formula: New Bio-Ink Can Depict the Cell Environment Even More Accurately

Optimized Formula: New Bio-Ink Can Depict the Cell Environment Even More Accurately

It should be biofunctional – that is, it should replicate the natural cellular environment as closely as possible – and it should be printable: bioink. Achieving both of these properties at the same time is an enormous challenge that conventional biomaterials often fail to meet. Together with two partner companies, researchers at the NMI have now taken an important […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp